Welcome to our dedicated page for HALBERD news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on HALBERD stock.
Halberd Corporation (OTC PINK:HALB) is a publicly traded company on the OTC Market, focusing on groundbreaking technologies and innovations. Recently, the company has been making strides in the field of Traumatic Brain Injury (TBI) mitigation and developing a patented LDN+ drug for active-duty military and veterans. The LDN+ drug is a combination of low-dose Naltrexone and Cyclobenzaprine, aimed at reducing anxiety, depression, addiction symptoms, PTSD, and Suicidal Ideation. Halberd Corporation's commitment to providing solutions for mental health issues facing military personnel underscores its dedication to making a positive impact on society.
Rhea-AI Summary
Halberd 's LDN+ Drug Enters Safety Trial Protocol for Military Active Duty and Veterans under CRADA Contract, Signaling Promising Developments in Addressing Mental Health Issues
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
-
Rhea-AI Summary
Halberd Corporation's Traumatic Brain Injury (TBI) nasal spray testing protocols were approved by the Institutional Animal Care and Use Committee at Mississippi State University. The company plans to launch an advanced program after the successful Phase #1 pilot test program. The CEO expressed optimism about the results and secured non-dilutive funding for future expenditures. Halberd also executed a revenue sharing agreement with Athena for further technology development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
-
Rhea-AI Summary
Halberd Corporation's executives discuss the partnership with Athena GTX and its potential impact on advancing breakthrough technologies towards government contracts. The interview on 'The Street Reports' sheds light on the optimistic outlook for 2024. For more information, visit the Halberd Corporation website or listen to the podcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
Rhea-AI Summary
Halberd Corporation (HALB) made significant advances in technology development and business goals in 2023, achieving successful eradication of antibiotic-resistant bacteria and fungi, as well as significant progress in developing a nasal spray to counteract Traumatic Brain Injury (TBI). The company also secured non-dilutive funding and joint ventures for continued R&D, clinical trials, and FDA certification of its products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.7%
Tags
-
News
Rhea-AI Summary
Halberd Corporation (HALB) announces revenue-sharing agreement with Athena GTX, Inc. for medical care solutions tailored for first responders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
-
Rhea-AI Summary
Halberd Corporation (HALB) formalizes revenue-sharing agreement with Athena GTX, Inc. specializing in medical care solutions for first responders. Athena has a successful history of securing government contracts, with 60% of its income historically coming from innovative research and development funding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.53%
Tags
Rhea-AI Summary
Halberd Corporation (HALB) and CrodenHealth.com of Canada have agreed to produce, market, sell, and distribute Halberd's patented low dose naltrexone combo products worldwide. The agreement also gives CrodenHealth.com the right of first refusal regarding similar rights to future products in Halberd's development pipeline. This partnership brings together the vast pharmaceutical sales and marketing expertise of CrodenHealth with Halberd Corporation's unique groundbreaking intellectual property and first-to-market products, ensuring a profitable positive impact on patient outcomes. The collaboration aims to create new and profitable revenue streams, marking the beginning of a long fruitful win-win relationship between the two entities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.29%
Tags
-
Rhea-AI Summary
Halberd Corporation (HALB) Extends Research Collaboration with Mississippi State University (MSU) for TBI Nasal Spray Project
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
-
Rhea-AI Summary
Halberd Corporation provides updates on important projects in recent interview
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.71%
Tags
Rhea-AI Summary
Halberd Corporation's nasal spray testing results show promising reductions in biomarkers associated with Traumatic Brain Injury (TBI). Neuron Specific Enolase (NSE) reduced by 25% and Glial Fibrillary Acid Protein (GFAP) reduced by 52.3%. The results indicate potential breakthrough in TBI treatment. The company aims to perfect the formulation and looks forward to feedback from the Department of Defense.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
FAQ
What is the current stock price of HALBERD (HALB)?
The current stock price of HALBERD (HALB) is $0.0032 as of December 20, 2024.
What is the market cap of HALBERD (HALB)?
The market cap of HALBERD (HALB) is approximately 2.0M.
What is Halberd Corporation focused on?
Halberd Corporation is a publicly traded company on the OTC Market, concentrating on innovative technologies and solutions, particularly in the areas of Traumatic Brain Injury (TBI) mitigation and mental health for military personnel.
What is the LDN+ drug developed by Halberd Corporation?
The LDN+ drug is a combination of low-dose Naltrexone and Cyclobenzaprine, designed to address anxiety, depression, addiction symptoms, PTSD, and Suicidal Ideation in active-duty military and veterans.
What recent developments has Halberd Corporation made?
Halberd Corporation has initiated pre-pilot studies with military volunteers to evaluate the LDN+ drug's safety and effectiveness. Additionally, the company has been actively involved in addressing Traumatic Brain Injury (TBI) through innovative solutions.
How is Halberd Corporation contributing to mental health solutions for military personnel?
Halberd Corporation's commitment to developing innovative solutions such as the LDN+ drug and TBI mitigation technologies demonstrates its dedication to providing mental health support for active-duty military and veterans.
HALBERD CORP